Create a narrative

Kiniksa Pharmaceuticals International Community

NasdaqGS:KNSA Community

1 Narratives written by author
0 Comments on narratives written by author
27 Fair Values set on narratives written by author

Kiniksa Pharmaceuticals International

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

Broader Biologic Adoption Will Unlock Undervalued Market Potential

Key Takeaways Widening market adoption and evolving treatment guidelines for ARCALYST are driving sustained revenue growth and strengthening the company's competitive stance. Diverse pipeline advances and strong financial discipline support long-term earnings growth, operational leverage, and continued innovation investment.

US$46.50

FV

28.2% undervalued

23.29%

Revenue growth p.a.

0

0

17

1 day ago